Xenon Pharmaceuticals XENE Gain (Loss), Foreign Currency Transaction, before Tax
Gain (Loss), Foreign Currency Transaction, before Tax at other companies
Other financials
Where this comes from
Reported directly by Xenon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ForeignCurrencyTransactionGainLossBeforeTax.
The official record: Xenon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Xenon Pharmaceuticals's gain (loss), foreign currency transaction, before tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Xenon Pharmaceuticals's gain (loss), foreign currency transaction, before tax?
- Xenon Pharmaceuticals (XENE) reported gain (loss), foreign currency transaction, before tax of $548K in Q1 2026.
- How has Xenon Pharmaceuticals's gain (loss), foreign currency transaction, before tax changed year-over-year?
- Xenon Pharmaceuticals's gain (loss), foreign currency transaction, before tax increased by 1465.7% year-over-year, from $35K to $548K.